Pharmaceutical companies continue to drive transparency and underline industry investment in Europe’s healthcare
Over the next ten days, pharmaceutical companies will disclose details of collaborations with health professionals (HCPs),healthcare organisations (HCOs) and patient organisations (POs) across Europe. The figures, which will be available online, underline industry’s continued investment in European healthcare, enabling the development of new medicines through sharing best clinical practice, exchanging information on how new medicines fit into the patient pathway and shaping the future of clinical research.
Director General of EFPIA, Nathalie Moll said, “Discovering, developing and delivering new medicines to patients is challenging. It often requires collaboration and dialogue, with patients, with healthcare professionals and with healthcare organisations. The transparency of these relationships is vital to build understanding and ensure confidence. That is why EFPIA and its members have committed to disclosing annually transfers of value to health professionals, healthcare organisations and patient organisations.”
Covering activities such as research and educational grants to healthcare organisations as well as transfers of value to individuals for activities such as speaking at educational meetings, consultancy and attending advisory boards as well as sponsorship to attend educational meetings, the disclosures will address transfers of value made during 2017.
Bringing greater transparency to these already well-regulated and essential relationships is about strengthening the basis for collaboration in the future. Interactions between industry, HCPs,HCOs and POs are vital to ensure we can continue to develop medicines that advance healthcare and continue to improve the lives of patients across Europe.